vs

Side-by-side financial comparison of CORCEPT THERAPEUTICS INC (CORT) and Knowles Corp (KN). Click either name above to swap in a different company.

CORCEPT THERAPEUTICS INC is the larger business by last-quarter revenue ($202.1M vs $153.1M, roughly 1.3× Knowles Corp). CORCEPT THERAPEUTICS INC runs the higher net margin — 12.0% vs 6.3%, a 5.7% gap on every dollar of revenue. On growth, Knowles Corp posted the faster year-over-year revenue change (22.7% vs 11.1%). CORCEPT THERAPEUTICS INC produced more free cash flow last quarter ($38.4M vs $-3.1M). Over the past eight quarters, CORCEPT THERAPEUTICS INC's revenue compounded faster (17.3% CAGR vs -13.5%).

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

Knowles Corporation is a global leading designer and manufacturer of advanced micro-acoustic, audio processing, and precision component solutions. It serves core segments including consumer electronics, automotive, medical technology, and industrial markets, offering products such as MEMS microphones, hearing aid components, and edge audio processing ICs to worldwide clients.

CORT vs KN — Head-to-Head

Bigger by revenue
CORT
CORT
1.3× larger
CORT
$202.1M
$153.1M
KN
Growing faster (revenue YoY)
KN
KN
+11.6% gap
KN
22.7%
11.1%
CORT
Higher net margin
CORT
CORT
5.7% more per $
CORT
12.0%
6.3%
KN
More free cash flow
CORT
CORT
$41.5M more FCF
CORT
$38.4M
$-3.1M
KN
Faster 2-yr revenue CAGR
CORT
CORT
Annualised
CORT
17.3%
-13.5%
KN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CORT
CORT
KN
KN
Revenue
$202.1M
$153.1M
Net Profit
$24.3M
$9.7M
Gross Margin
98.7%
43.8%
Operating Margin
2.2%
10.4%
Net Margin
12.0%
6.3%
Revenue YoY
11.1%
22.7%
Net Profit YoY
-21.0%
585.0%
EPS (diluted)
$0.20
$0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CORT
CORT
KN
KN
Q1 26
$153.1M
Q4 25
$202.1M
$162.2M
Q3 25
$207.6M
$152.9M
Q2 25
$194.4M
$145.9M
Q1 25
$157.2M
$132.2M
Q4 24
$181.9M
$142.5M
Q3 24
$182.5M
$142.5M
Q2 24
$163.8M
$204.7M
Net Profit
CORT
CORT
KN
KN
Q1 26
$9.7M
Q4 25
$24.3M
$21.0M
Q3 25
$19.7M
$17.4M
Q2 25
$35.1M
$7.8M
Q1 25
$20.5M
$-2.0M
Q4 24
$30.7M
$18.5M
Q3 24
$47.2M
$500.0K
Q2 24
$35.5M
$-259.3M
Gross Margin
CORT
CORT
KN
KN
Q1 26
43.8%
Q4 25
98.7%
44.7%
Q3 25
97.8%
45.7%
Q2 25
98.2%
41.5%
Q1 25
98.5%
40.3%
Q4 24
98.4%
42.7%
Q3 24
98.4%
44.1%
Q2 24
98.5%
28.2%
Operating Margin
CORT
CORT
KN
KN
Q1 26
10.4%
Q4 25
2.2%
15.9%
Q3 25
4.9%
16.9%
Q2 25
13.7%
10.1%
Q1 25
2.2%
3.0%
Q4 24
13.9%
10.8%
Q3 24
25.5%
13.1%
Q2 24
21.7%
6.2%
Net Margin
CORT
CORT
KN
KN
Q1 26
6.3%
Q4 25
12.0%
12.9%
Q3 25
9.5%
11.4%
Q2 25
18.1%
5.3%
Q1 25
13.1%
-1.5%
Q4 24
16.9%
13.0%
Q3 24
25.9%
0.4%
Q2 24
21.7%
-126.7%
EPS (diluted)
CORT
CORT
KN
KN
Q1 26
$0.13
Q4 25
$0.20
$0.23
Q3 25
$0.16
$0.20
Q2 25
$0.29
$0.09
Q1 25
$0.17
$-0.02
Q4 24
$0.25
$0.20
Q3 24
$0.41
$0.01
Q2 24
$0.32
$-2.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CORT
CORT
KN
KN
Cash + ST InvestmentsLiquidity on hand
$372.2M
$41.0M
Total DebtLower is stronger
$131.0M
Stockholders' EquityBook value
$647.8M
$780.2M
Total Assets
$836.7M
$1.1B
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CORT
CORT
KN
KN
Q1 26
$41.0M
Q4 25
$372.2M
$54.2M
Q3 25
$421.7M
$92.5M
Q2 25
$342.2M
$103.2M
Q1 25
$322.8M
$101.9M
Q4 24
$383.3M
$130.1M
Q3 24
$380.3M
$92.6M
Q2 24
$473.2M
$84.0M
Total Debt
CORT
CORT
KN
KN
Q1 26
$131.0M
Q4 25
$114.0M
Q3 25
$176.3M
Q2 25
$190.0M
Q1 25
$188.8M
Q4 24
$202.5M
Q3 24
$225.0M
Q2 24
$261.2M
Stockholders' Equity
CORT
CORT
KN
KN
Q1 26
$780.2M
Q4 25
$647.8M
$775.8M
Q3 25
$631.9M
$751.8M
Q2 25
$635.8M
$746.1M
Q1 25
$683.3M
$755.8M
Q4 24
$679.6M
$756.0M
Q3 24
$638.8M
$777.4M
Q2 24
$596.2M
$753.0M
Total Assets
CORT
CORT
KN
KN
Q1 26
$1.1B
Q4 25
$836.7M
$1.1B
Q3 25
$823.6M
$1.1B
Q2 25
$801.7M
$1.1B
Q1 25
$846.5M
$1.1B
Q4 24
$840.6M
$1.1B
Q3 24
$784.3M
$1.2B
Q2 24
$714.6M
$1.2B
Debt / Equity
CORT
CORT
KN
KN
Q1 26
0.17×
Q4 25
0.15×
Q3 25
0.23×
Q2 25
0.25×
Q1 25
0.25×
Q4 24
0.27×
Q3 24
0.29×
Q2 24
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CORT
CORT
KN
KN
Operating Cash FlowLast quarter
$38.4M
$0
Free Cash FlowOCF − Capex
$38.4M
$-3.1M
FCF MarginFCF / Revenue
19.0%
-2.0%
Capex IntensityCapex / Revenue
0.0%
7.1%
Cash ConversionOCF / Net Profit
1.58×
0.00×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CORT
CORT
KN
KN
Q1 26
$0
Q4 25
$38.4M
Q3 25
$54.5M
$29.1M
Q2 25
$43.9M
$36.4M
Q1 25
$5.1M
$1.3M
Q4 24
$59.3M
Q3 24
$73.8M
$52.8M
Q2 24
$41.2M
$24.9M
Free Cash Flow
CORT
CORT
KN
KN
Q1 26
$-3.1M
Q4 25
$38.4M
Q3 25
$21.4M
Q2 25
$43.9M
$31.3M
Q1 25
$5.0M
$-2.7M
Q4 24
$59.2M
Q3 24
$72.2M
$49.1M
Q2 24
$40.8M
$21.7M
FCF Margin
CORT
CORT
KN
KN
Q1 26
-2.0%
Q4 25
19.0%
Q3 25
14.0%
Q2 25
22.6%
21.5%
Q1 25
3.2%
-2.0%
Q4 24
32.5%
Q3 24
39.5%
34.5%
Q2 24
24.9%
10.6%
Capex Intensity
CORT
CORT
KN
KN
Q1 26
7.1%
Q4 25
0.0%
9.4%
Q3 25
0.0%
5.0%
Q2 25
0.0%
3.5%
Q1 25
0.1%
3.0%
Q4 24
0.1%
2.3%
Q3 24
0.9%
2.6%
Q2 24
0.3%
1.6%
Cash Conversion
CORT
CORT
KN
KN
Q1 26
0.00×
Q4 25
1.58×
Q3 25
2.77×
1.67×
Q2 25
1.25×
4.67×
Q1 25
0.25×
Q4 24
1.93×
Q3 24
1.56×
105.60×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons